COMMUNIQUÉS West-GlobeNewswire

Avacta Group plc: Faridoxorubicin Treatment Results in Near Doubling of Progression-Free Survival and Clinically Meaningful Tumor Shrinkage in Most Patients with Salivary Gland Cancers
26/10/2026
Durability of faridoxorubicin (AVA6000) activity results from the continued release of doxorubicin by fibroblast activation protein (FAP) demonstrated beyond 10 cycles of therapy FAPI-PET imaging data indicate prolonged [...]
Imprivata Recognized for the First Time in the Gartner® Magic Quadrant™ for Privileged Access Management
26/10/2026
Imprivata combines privileged, agentic AI, and third-party access management into a single comprehensive platform to help organizations reduce risk, meet regulatory compliance requirements, and improve operational [...]
More Than 1 in 10 People Receive Medically Actionable Genetic Results Through 23andMe, Analysis of Nearly 6 Million Participants Finds
26/10/2026
Early findings presented at ASHG 2026 indicate nearly all people choose to learn their genetic health risks when given the option PALO ALTO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- New research from 23andMe Research [...]
Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call
26/10/2026
CERRITOS, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (“STLN”) (NASDAQ: STLN) a pioneer in value-based community oncology care, today announced that the company will release its third quarter 2026 [...]
SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics’ Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
26/10/2026
UC Davis is the primary manufacturing site for CER-1236, site activation is expected to expand patient recruitment capacity and streamline treatment logistics Update follows SRX’s previously announced definitive [...]
Major shareholder announcement
26/10/2026
Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis has received a major shareholder notification from BlackRock, Inc. regarding its holdings in Novonesis. As of October 22, 2026, BlackRock, Inc.’s [...]
X9 Receives FDA Breakthrough Device Designation for Investigational Dialysis Cannulation System and Completes Second Clinical Study
26/10/2026
ACCESS-2 study provides additional clinical experience with X9's investigational technology for vascular access in hemodialysis WALLINGFORD, Conn., Oct. 26, 2026 (GLOBE NEWSWIRE) -- X9, Inc., a privately held medical [...]
Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
26/10/2026
Important Secondary Clinical Outcome Endpoint MACE Achieved Statistical Significance ELPIS II 2 Data in HLHS Selected for Late-Breaking Science Program Podium Presentation in the American Heart Association’s (AHA) 2026 [...]
NeOnc Targets Major Brain Cancer Trial Expansion with 500 Patients Across 30 Hospitals in Three Countries
26/10/2026
Health Uncensored with Dr. Drew spotlights ambitious international trial plans, a novel delivery approach and the patient experiences driving NeOnc’s research DENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews. [...]
U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week
26/10/2026
Vadadustat demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen WALTHAM, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Akebia [...]
Transactions under Novonesis’ share buyback program
26/10/2026
Please read the announcement in PDF Attachment 2026_25_Share_buyback
Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026
26/10/2026
REDWOOD CITY, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc . (Nasdaq: CHRS), today announced that its third quarter 2026 financial results will be released on Monday, November 9, 2026. Starting at 5: [...]
Phathom Pharmaceuticals Provides Update on FDA Litigation
26/10/2026
FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) [...]
NTG Nordic Transport Group A/S - Upgrade of guidance for the full year 2026
26/10/2026
Company announcement no. 41 – 26 26 October 2026 NTG Nordic Transport Group A/S - Upgrade of guidance for the full year 2026 Based on preliminary financial results for the third quarter of 2026, NTG expects adjusted [...]
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
26/10/2026
— ORPATHYS ® plus TAGRISSO ® reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting — — Robust PFS gains alongside [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
26/10/2026
COPENHAGEN, Denmark, October 26, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount [...]
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
26/10/2026
MAINZ, Germany and SHANGHAI, China, October 26, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and DualityBiologics (Suzhou) Co., Ltd. (“DualityBio”, HKEX: 9606.HK) announced today that the DYNASTY-Breast02 global Phase [...]
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
26/10/2026
TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolerability profile [...]
A new scientific avenue for daridorexant: Idorsia to advance development in autism spectrum disorder
26/10/2026
Ad hoc announcement pursuant to Art. 53 LR In a Phase 2 study in pediatric insomnia disorder, in addition to marked improvements in sleep measures, daridorexant 50 mg showed an unexpected pattern of improvement in [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum